Weight-Loss Drugs Have Negligible Impact on PepsiCo Sales, CEO States

PepsiCo's CEO, Ramon Laguarta, has stated that the impact of weight-loss drugs like Ozempic and Wegovy on their sales has been minimal so far. While acknowledging some uncertainty about the long-term effects of these drugs on consumer behavior, the company remains watchful of the trend. Laguarta highlighted a shift toward more snacking and mini-meals, particularly among urban, middle-class consumers, as a positive development for PepsiCo.